Hadasit Ltd., Hadassah Medical Organization and Brigham and Women's Hospital Announce the Successful Phase I Study Results of a New Orally Administered Drug for Autoimmune Diseases

Published: Apr 16, 2008

JERUSALEM & BOSTON--(BUSINESS WIRE)--Hadasit, the technology transfer company of Hadassah Medical Organization in Jerusalem, and Brigham and Women’s Hospital (BWH), a teaching affiliate of Harvard Medical School, announced today the successful results of a Phase I study of a new orally administered drug for immune mediated diseases such as diabetes, Crohn's disease, psoriasis, multiple sclerosis, and liver diseases. The trial was announced in January 2008.

Back to news